Quick answer: TB-500 commonly refers to a synthetic fragment associated with thymosin beta-4. No FDA-approved TB-500 drug exists. FDA has reported that it lacks adequate human exposure and safety information for the fragment commonly marketed under this name.

How to use this profile

This profile separates the status of TB-500 from evidence about a particular product, formulation, route, or claim. Read the status and product-context section first, then use the evidence and safety sections to test whether an online claim actually matches the material being promoted.

Editorial standard: mechanism, laboratory findings, animal research, human trials, product approval, compounding, and research-only sales are treated as different evidence and regulatory categories. Similar ingredient names do not prove product equivalence.

Status and identity

Status snapshot

TB-500 is an unapproved research compound. It has been evaluated in the federal compounding discussion, but nomination or advisory review is not product approval and does not establish a safe personal-use protocol.

Identity confusion matters

Online discussions often use \u201cTB-500,\u201d \u201cthymosin beta-4,\u201d and thymosin beta-4 fragments as if they were identical. They may not be. Sequence length, acetylation, salt form, formulation, and biological behavior can differ. Evidence about the full naturally occurring protein cannot automatically be transferred to a short synthetic fragment.

Sequence documentation is essential

A credible analytical record should identify the exact amino-acid sequence, molecular formula or expected mass, and salt form. \u201cTB-500\u201d alone can be too ambiguous to connect a test result with the material discussed in a paper.

Evidence and claim interpretation

Why wound-healing claims spread

Thymosin beta-4 biology has been studied in tissue repair, cell migration, angiogenesis, and inflammation. Those mechanisms make compelling marketing language. They do not prove that a retail TB-500 vial improves human tendon, muscle, or surgical recovery.

Human evidence gaps

FDA has stated that it has not identified adequate human exposure data for the thymosin beta-4 fragment commonly called TB-500. Without well-controlled human studies, the magnitude of benefit, dose-response relationship, adverse-event profile, and long-term effects remain uncertain.

Angiogenesis claims need balance

Processes involving blood-vessel formation can be relevant to repair biology, but biological pathways can have different effects in different tissues and disease contexts. A mechanism should not be described as universally beneficial.

Safety, quality, and verification

FDA-identified concerns

FDA has discussed immunogenicity, aggregation, peptide-related impurities, and limited characterization. These concerns are particularly important for injectable products because injection bypasses several of the body’s external defenses.

Marketing red flags

Using thymosin beta-4 research as direct proof for TB-500
Promising accelerated healing without controlled human data
Publishing \u201cstacks\u201d that combine TB-500 with BPC-157
Presenting a seller COA as proof of clinical safety
Ignoring anti-doping and athletic-governing-body rules

Combination protocols add uncertainty

TB-500 is frequently marketed with BPC-157. Combining two inadequately characterized compounds does not create stronger evidence. It makes adverse effects, interactions, and attribution more difficult to evaluate.

Quality questions

Ask whether the actual sequence and salt form are identified, whether the lot matches the COA, and whether testing includes assay as well as identity and purity. For any injectable claim, sterility and endotoxin are separate from HPLC purity.

Adverse events may be undercounted

Research-chemical use often occurs without systematic monitoring or traceable product records. That makes it difficult to estimate event rates or connect a reaction to identity, dose, contamination, or another compound in a stack.

Bottom line

TB-500 remains a research-only compound with unresolved identity, effectiveness, and safety questions. Treat seller protocols and recovery testimonials as marketing\u2014not clinical guidance.

Related reading: research-use labels, COA interpretation, and vendor red flags.